- Featured Product
- KD/KO Validated
CISD2 Polyclonal antibody
CISD2 Polyclonal Antibody for FC, IF, IHC, IP, WB, ELISA
Cat no : 13318-1-AP
|Positive WB detected in||mouse kidney tissue, mouse brain tissue, human brain tissue, HeLa cells, mouse heart tissue|
|Positive IP detected in||mouse brain tissue|
|Positive IHC detected in||human kidney tissue, human brain tissue, human lung tissue, human ovary tissue, human pancreas tissue, human spleen tissue, human testis tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HepG2 cells|
|Positive FC detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
13318-1-AP targets CISD2 in WB, IP, IHC, IF, FC, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||Drosophila, human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||CISD2 fusion protein Ag4172|
|Full Name||CDGSH iron sulfur domain 2|
|Calculated molecular weight||135 aa, 15 kDa|
|Observed molecular weight||13-15 kDa|
|GenBank accession number||BC032300|
|Gene ID (NCBI)||493856|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
CISD2 gene encodes a 15 kDa CDGSH iron-sulfur domain-containing protein 2, which is also named Miner1 or NAF-1, this protein was reported on endoplasmic reticulum membrane or mitochondrion outer membrane. Defects in CISD2 are the cause of Wolfram syndrome type 2 (WFS2), a rare disorder characterized by juvenile-onset insulin-dependent diabetes mellitus with optic atrophy. CISD2 regulates autophagy program by interacting BCL2, contributing to antagonize BECN1-mediated cellular autophagy at the endoplasmic reticulum.
|Product Specific Protocols|
|WB protocol for CISD2 antibody 13318-1-AP||Download protocol|
|IHC protocol for CISD2 antibody 13318-1-AP||Download protocol|
|IF protocol for CISD2 antibody 13318-1-AP||Download protocol|
|IP protocol for CISD2 antibody 13318-1-AP||Download protocol|
|FC protocol for CISD2 antibody 13318-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Int J Clin Exp Pathol
CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma.
CISD2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer.
BMC Med Genet
A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients.
Genetic studies in Drosophila and humans support a model for the concerted function of CISD2, PPT1 and CLN3 in disease.
CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway.
Dysfunction in the mitochondrial Fe-S assembly machinery leads to formation of the chemoresistant truncated VDAC1 isoform without HIF-1α activation.